Cancer Center, Sun Yat-sen University
Guangzhou, Guangdong, 510060, China
Location status: Recruiting
NCT Number: NCT04544969
The prospective observational clinical study will recruit 50 metastatic nasopharyngeal carcinoma (mNPC) patients, detecting patient's chemosensitivity with the circulating tumor cells (CTCs) from peripheral blood and prdicting patient's treatment efficacy with CTCs dynamic change.
Interested in participating?
Request Info18 year–70 year
All sexes
Observational
Guangzhou, Guangdong, 510060, China
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
GP: cisplatin 80 mg/m2 intravenous infusion on day1, gemcitabine 1000 mg/m2 intravenous infusion on day 1 and 8, both drugs are given every 3 weeks, recommended 6 cycles.
TP: cisplatin 75 mg/m2 intravenous infusion in day1, docetaxel 75 mg/m2 intravenous infusion in day 1, both drugs are given every 3 weeks, recommended 6 cycles.
PF: cisplatin 100 mg/m2 intravenous infusion in day1, fluorouracil 4000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.
TPF: cisplatin 60 mg/m2 intravenous infusion in day1, docetaxel 60 mg/m2 intravenous infusion in day 1, fluorouracil 3000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.
Choice of chemotherapy regimen is decided by patient's doctor in charge.
Other names: docetaxel and cisplatin, fluorouracil and cisplatin, docetaxel, fluorouracil and cisplatin, gemcitabine and cisplatin
Time frame: 6 months
Comparison the coincidence rate between drug sensitivity test in CTCs and objective response rate of corresponding chemotherapy regime
Time frame: Change from pre-chemotherapy to 22-28(±7) days after last course of chemotherapy
Time frame: study period of 19 Months
To be determined by measurement of target lesions according to RECIST criteria
Time frame: baseline
Defined as the time in months from first course of treatment until PD is observed or death occurs due to any cause.
Time frame: Objective response at 6 months
to identify patients with early relapse (<6 months) after liver resection as determined by the AUC under the ROC curve
Time frame: Change from pre-chemotherapy to 22-28(±7) days after last course of chemotherapy
Contact information is provided by the study sponsor or research team.
Sun Yat-sen University
Other
Detecting Chemosensitivity and Predicting Treatmemt Efficacy With Circulating Tumour Cells From Peripheral Blood in Metastatic Nasopharyngeal Carcinoma Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05346536
Circulating Tumor Cell, Digestive System Diseases
Montpellier, France
View Trial DetailsNCT05360290
Breast Cancer, Breast Diseases
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT06755762
Carcinoma, Carcinoma, Squamous Cell
Taoyuan, Taiwan
View Trial DetailsNCT06391892
Circulating Tumor Cell, Digestive System Diseases
Linz, Upper Austria, Austria
View Trial Details